The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing.
Khalifa AlrajehYoussef M RomanPublished in: Pharmacogenomics (2023)
Statins are widely used medications for the primary and secondary prevention of cardiovascular diseases. Statin-induced musculoskeletal symptoms are the primary adverse drug events contributing to poor adherence to lipid-lowering therapy. Rosuvastatin is characterized by interindividual differences in systemic exposure among different patient population subgroups. The missense variant Q141K within ABCG2 , highly prevalent in some Asian subgroups, results in decreased transporter efflux function and increased exposure to rosuvastatin. We aim to highlight the implications of ABCG2 genotype in prescribing rosuvastatin and the ramifications of interpopulation differences in Q141K frequencies in the starting dose of rosuvastatin in major Asian subgroups, using the most recent genetic-based guidelines. The high frequency of Q141K in Filipinos could warrant a lower starting rosuvastatin dose versus non-Filipinos. The Q141K genotype frequencies in Asian subgroups suggest significant interpopulation differences, reinforcing the need to move beyond race-based to genotype-based rosuvastatin dosing.
Keyphrases
- high frequency
- adverse drug
- cardiovascular disease
- transcranial magnetic stimulation
- primary care
- emergency department
- type diabetes
- stem cells
- physical activity
- gene expression
- oxidative stress
- autism spectrum disorder
- electronic health record
- diabetic rats
- dna methylation
- fatty acid
- metabolic syndrome
- weight loss
- mesenchymal stem cells
- insulin resistance
- cell therapy
- stress induced
- low density lipoprotein